LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "novartis pfizer" as a keyword



OA14 Non-steroidal anti-inflammatory drugs reduce sacroiliac joint inflammation in axial spondyloarthritis

Sign Up to like & get
recommendations! Published in 2023 at "Rheumatology"

DOI: 10.1093/rheumatology/kead104.014

Abstract: MRI evidence of active sacroiliitis (sacroiliac joint bone marrow oedema (BMO)) is commonly used to assist diagnosis and classification of axial spondyloarthritis (axSpA). Non-steroidal anti-inflammatory drugs (NSAIDs) are used as first-line therapy, and for persistent… read more here.

Keywords: rheumatology; novartis pfizer; sacroiliac joint; pfizer ... See more keywords

P134 Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from two Phase 3 Studies

Sign Up to like & get
recommendations! Published in 2023 at "Rheumatology"

DOI: 10.1093/rheumatology/kead104.175

Abstract: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life; however, there are no accepted criteria for identifying axial involvement in PsA. The objective of this post-hoc analysis… read more here.

Keywords: novartis pfizer; investigator assessment; abbvie; axial involvement ... See more keywords

P112 The Impact of Filgotinib on Disease Activity Outcomes With Concomitant Pain Control in the Phase 3 FINCH Studies

Sign Up to like & get
recommendations! Published in 2024 at "Rheumatology"

DOI: 10.1093/rheumatology/keae163.153

Abstract: Patients with rheumatoid arthritis (RA) often experience substantial pain despite treatment, and consider pain control an important treatment outcome. This post-hoc analysis of the FINCH studies assessed specific effects of filgotinib (FIL) on pain and… read more here.

Keywords: eli lilly; pain; group; consultancies abbvie ... See more keywords

E067 Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drugnaïve patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, activereference study

Sign Up to like & get
recommendations! Published in 2024 at "Rheumatology"

DOI: 10.1093/rheumatology/keae163.294

Abstract: Given the chronic nature of psoriatic arthritis (PsA), sustaining high levels of disease control with treatment is important. Assessing maintenance of response in patients that achieve treatment targets is of interest as loss of response… read more here.

Keywords: pharma; eli lilly; ucb pharma; novartis pfizer ... See more keywords

OA16 Bimekizumab treatment resulted in improvements in MRI inflammatory and structural lesions in the sacroiliac joints of patients with axial spondyloarthritis: 52-week results and post hoc analyses from two Phase 3 studies

Sign Up to like & get
recommendations! Published in 2025 at "Rheumatology"

DOI: 10.1093/rheumatology/keaf142.016

Abstract: The impact of dual inhibition of interleukin (IL)17F in addition to IL-17A with bimekizumab (BKZ) on structural lesions in axial spondyloarthritis (axSpA) patients has not yet been shown. We report BKZ impact on MRI inflammatory… read more here.

Keywords: bkz; axspa; research; pfizer ... See more keywords

OP0334 Efficacy and safety of continuing versus withdrawing adalimumab (ADA) in maintaining remission in patients with non-radiographic axial spondyloarthritis (NR-AXSPA)

Sign Up to like & get
recommendations! Published in 2018 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2018-eular.2641

Abstract: Tapering and flaring in PsA and SpA Background It is not known whether TNF blockers can be stopped in nr-axSpA patients (pts) who are in remission. Objectives ABILITY-3, reported here, assessed if ADA can be… read more here.

Keywords: abbvie; ada; pbo; novartis pfizer ... See more keywords

FRI0426 IXEKIZUMAB MAKES REMISSION AND LOW DISEASE ACTIVITY POSSIBLE IN PATIENTS WITH PSORIATIC ARTHRITIS: TWO-YEAR RESULTS IN TNF INADEQUATE RESPONDERS OR BIOLOGIC-NAïVE PATIENTS

Sign Up to like & get
recommendations! Published in 2019 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2019-eular.1225

Abstract: Background Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease that can involve peripheral and axial joints, skin, and entheses. A number of validated composite indices have been developed, not only to measure overall disease activity… read more here.

Keywords: pfizer; novartis pfizer; disease; eli lilly ... See more keywords

FRI0429 NON TOPICAL PHARMACOLOGICAL TREATMENT OF EARLY, UNTREATED (DMARD-NAïVE, SYSTEMIC THERAPY-NäIVE) PSORIATIC DISEASE: A SYSTEMATIC REVIEW

Sign Up to like & get
recommendations! Published in 2019 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2019-eular.1837

Abstract: Background Psoriatic disease (PsD) refers to a systemic condition, probably driven by chronic and complex inflammatory mechanisms. PsD patients experience a fickle mixture of cutaneous (nail dystrophy, psoriatic lesions spectrum) and musculoskeletal (MSK: arthritis, enthesitis,… read more here.

Keywords: lilly novartis; celgene; consultant; research ... See more keywords

FRI0437 PATIENT-DEFINED FLARES IN IN PSORIATIC ARTHRITIS: WHAT DO THEY MEAN? AN ANALYSIS OF CHANGE BETWEEN 2 VISITS IN 222 PATIENTS

Sign Up to like & get
recommendations! Published in 2019 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2019-eular.2161

Abstract: Background In psoriatic arthritis (PsA), disease fluctuations lead to periods of flares which impact patients’ lives and treatment retention, these flares have been little studied. Objectives To explore the frequency of flares in patients with… read more here.

Keywords: pfizer; novartis pfizer; disease; celgene ... See more keywords

THU0359 WHAT IS THE LEVEL OF AGREEMENT BETWEEN LOCAL AND CENTRAL READERS IN THE DETECTION OF ACTIVE AND STRUCTURAL LESIONS ON MRI TYPICAL OF AXIAL SPONDYLOARTHRITIS? DATA FROM THE ASAS CLASSIFICATION COHORT STUDY

Sign Up to like & get
recommendations! Published in 2019 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2019-eular.3158

Abstract: Background There has been no central reader evaluation of MRI scans from the ASAS Classification Cohort (ASAS-CC)1 to compare detection of lesions in the sacroiliac joints (SIJ) between central and ASAS-CC local site readers. Active… read more here.

Keywords: pfizer; central readers; novartis pfizer; structural lesions ... See more keywords

THU0358 DEVELOPMENT OF A SET OF ASAS QUALITY STANDARDS FOR ADULTS WITH AXIAL SPONDYLOARTHRITIS

Sign Up to like & get
recommendations! Published in 2019 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2019-eular.4555

Abstract: Background: There is wide variation in the management of patients with axial spondyloarthritis (axSpA) worldwide with significant unmet needs such as delayed diagnosis. A major goal of the international organization Assessment of SpondyloArthritis international Society… read more here.

Keywords: none declared; pfizer; novartis pfizer; celgene ... See more keywords